Kairos Pharma

Menu
INVESTORS
CONTACT

About Kairos Pharma

Cutting-Edge Cancer Solutions

Backed by science and driven by innovation, we are redefining the future of cancer treatment.

Learn More

A New Era

In Cancer Therapy

Pioneering Breakthroughs in Cancer Treatment

Kairos Pharma is a clinical-stage biopharmaceutical company committed to developing innovative therapies that combat drug resistance and immune suppression in cancer patients. Our mission is to push the boundaries of medical science and improve outcomes for those facing the toughest battles.

A Targeted Approach to Drug Resistance

Our lead candidate, ENV105, is a groundbreaking antibody designed to target CD105—a protein known to drive resistance to various cancer treatments. By inhibiting CD105 on cancer cells, ENV105 works to restore the effectiveness of standard therapies, offering new hope to patients across multiple cancer

Advancing Through
Clinical Trials

ENV105 is currently undergoing rigorous testing to bring its benefits to patients. It is in Phase 2 clinical trials for prostate cancer and Phase 1 trials for lung cancer, addressing critical unmet medical needs and paving the way for more effective cancer treatments.

Meet The

Board of Directors

John S. Yu

CEO & Chairman

Rahul Singvhi

Hyun W. Bae

Michael Keyoung

Join Us On Our Mission

We are a dynamic company driving innovation at the forefront of cancer research. Our therapies are set to revolutionize cancer drug interactions and help extend the lives of our patients.

Investor Relations

About Kairos Pharma

Cutting-Edge Cancer Solutions

Backed by science and driven by innovation, we are redefining the future of cancer treatment.

Learn More

A New Era

In Cancer Therapy

Pioneering Breakthroughs in Cancer Treatment

Kairos Pharma is a clinical-stage biopharmaceutical company committed to developing innovative therapies that combat drug resistance and immune suppression in cancer patients. Our mission is to push the boundaries of medical science and improve outcomes for those facing the toughest battles.

A Targeted Approach to Drug Resistance

Our lead candidate, ENV105, is a groundbreaking antibody designed to target CD105—a protein known to drive resistance to various cancer treatments. By inhibiting CD105 on cancer cells, ENV105 works to restore the effectiveness of standard therapies, offering new hope to patients across multiple cancer

Advancing Through
Clinical Trials

ENV105 is currently undergoing rigorous testing to bring its benefits to patients. It is in Phase 2 clinical trials for prostate cancer and Phase 1 trials for lung cancer, addressing critical unmet medical needs and paving the way for more effective cancer treatments.

Meet The

Board of Directors

John S. Yu

CEO & Chairman

Rahul Singvhi

Hyun W. Bae

Michael Keyoung

Join Us On Our Mission

We are a dynamic company driving innovation at the forefront of cancer research. Our therapies are set to revolutionize cancer drug interactions and help extend the lives of our patients.

Investor Relations

About Kairos Pharma

Backed by science and driven by innovation, we are redefining the future of cancer treatment.

Learn More

A New Era

In Cancer Therapy

Pioneering Breakthroughs in Cancer Treatment

Kairos Pharma is a clinical-stage biopharmaceutical company committed to developing innovative therapies that combat drug resistance and immune suppression in cancer patients. Our mission is to push the boundaries of medical science and improve outcomes for those facing the toughest battles.

A Targeted Approach to
Drug Resistance

Our lead candidate, ENV105, is a groundbreaking antibody designed to target CD105—a protein known to drive resistance to various cancer treatments. By inhibiting CD105 on cancer cells, ENV105 works to restore the effectiveness of standard therapies, offering new hope to patients across multiple cancer

Advancing Through
Clinical Trials

ENV105 is currently undergoing rigorous testing to bring its benefits to patients. It is in Phase 2 clinical trials for prostate cancer and Phase 1 trials for lung cancer, addressing critical unmet medical needs and paving the way for more effective cancer treatments.

Meet The

Management Team

John S. Yu

CEO & Chairman

Doug Samuelson

Chief Financial Officer

Ramchandran Murali

VP, Research and Development

Neil Bhowmick

Chief Scientific Officer

Join Us On Our Mission

We are a dynamic company driving innovation at the forefront of cancer research. Our therapies are set to revolutionize cancer drug interactions and help extend the lives of our patients.

Investor Relations

BAS from Stanford, MD from Harvard Medical School and MIT

John S. Yu

CEO & Chairman

BAS from Stanford, MD from Harvard Medical School and MIT

  • Professor of Neurosurgery, Director Surgical Neuro-Oncology at Cedars-Sinai Medical Center
  • Numerous patents for immunotherapies and nanotechnologies from his NIH funded laboratory
  • Developed 8 new investigational drugs with the FDA and has led numerous clinical trials
  • Most recently CEO and Chairman of AcTcell, and Director of Enviro Therapeutics
  • Immunology Fellowship at the Institute Pasteur, Paris, Neurosurgery Residency at Massachusetts General Hospital/Harvard

Doug Samuelson

Chief Financial Officer

  • 25+ year finance and accounting professional 
  • Former CFO of Wellness Center USA
  • Former Director of Accounting of Second Sight Medical Products, Inc .
  • Former Chief Financial Officer of AdvaVet, Inc. and Chief Financial Officer of Solis Tek, Inc.
  • CPA in State of California

Professor, Biomedical Sciences and Research in Immunology at Penn/Cedars-Sinai Medical Center.

Ramchandran Murali

VP, Research and Development

Professor, Biomedical Sciences and Research in Immunology at Penn/Cedars-Sinai Medical Center.

  • Leading expert in X-ray crystallography, biophysical, biochemical, and immunology fields, having made significant advances in molecular engineering and cell surface receptors by developing pharmacological agents which include new paradigms in structure-based peptidomimetics drug discovery
  • Developed numerous technologies that reverse key mechanisms of immune suppression of cancer

Professor of the Department of Medicine and Director of the Cancer Biology Program at Cedars-Sinai Medical Center.

Neil Bhowmick

Chief Scientific Officer & President

Professor of the Department of Medicine and Director of the Cancer Biology Program at Cedars-Sinai Medical Center.

  • Fellowship at Vanderbilt University Medical Center Research Director, Oppenheimer Urologic Reference Laboratory (OURLab)
  • Holds 6 patents for biomarker detection platforms and stromal targeted therapeutics (inclusive of ENV105 and ENV205)
  • Consultant at Xencor Inc. (NASDAQ: XNCR) and Tracon Pharma (NASDAQ: TCON)
  • NCI/NIH funded for over 15 years and cited over 11,700 times

M.S. and Sc.D. degrees in chemical engineering from MIT. MBA from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar.

Rahul Singhvi

M.S. and Sc.D. degrees in chemical engineering from MIT. MBA from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar.

  • Global leader in the Life Sciences industry and is cofounder of the biomanufacturing company, Resilience (National Resilience, Inc.).
  • Former Operating Partner at Flagship Pioneering, where he founded and operated companies launched from Flagship’s innovation foundry, Flagship labs.
  • Former Chief Operating Officer of Takeda’s Vaccine Business Unit where he led worldwide vaccine CMC manufacturing.
  • Former President and CEO of Novavax, Inc. where he transformed the company from a specialty pharmaceutical business into a vaccine development company.
  • Career began at Merck & Co in 1994, where he held several positions in R&D and manufacturing.
  • Serves on the Board of Trustees of the Keck Graduate Institute, and on the Board of Directors for Codexis (Nasdaq:CDXS), and Garuda Therapeutics (private).

BS in Biomechanics from Columbia, MD cum laude from Yale, former NIH Howard Hughes Research Fellow Bethesda, MD

Hyun W. Bae

BS in Biomechanics from Columbia, MD cum laude from Yale, former NIH Howard Hughes Research Fellow Bethesda, MD

  • Professor of Surgery in Orthopaedic Surgery at CSMC, Director of Education and clinical partner of the Orthopaedic Stem Cell and Tissue Engineering Laboratory
  • 10+ years experience in drug development, PI for 3-4 FDA-approved randomized clinical trials with over 30 clinical studies, 60+ published scientific papers, 5 review articles and 30 patents
  • Chief Medical Officer and Director of Prosidyan, Scientific Advisory Board Member of Mesoblast, Tissuegene, Spine Biopharma and Engage Surgical

MD and Ph.D. in Neuroscience and Neurology from Cornell and Sloan Kettering (MSKCC), UCSF Health, Biomedical Fellow at Rockefeller and MSKCC.

Michael Keyoung

MD and Ph.D. in Neuroscience and Neurology from Cornell and Sloan Kettering (MSKCC), UCSF Health, Biomedical Fellow at Rockefeller and MSKCC.

  • Senior ME for CBC Group, a healthcare-dedicated PE firm with over US$9 Billion AUM
  • 20+ year career as a physician, executive and institutional investor in US, Europe and Asia advising Eli Lilly, Bausch & Lomb, and Samsung Electronics/Biologics on Asian expansion, global drug development and commercial/partnership strategies
  • Former CEO of Genexine (KOSDAQ: 095700 w/ $1 Billion MC), led clinical development in Europe and Asia, raised $100M and created partnerships with Merck, Fosun Pharma, Tasly Pharma and Kalbe Pharma valued at over $250M
  • Former President of Catalyst Biosciences, (NASDAQ: CBIO) a clinical stage hemophilia and ophthalmology company partnered with Pfizer, MedImmune and Isu Abxis
  • Previous Board Chair of AffaMed Therapeutics and Director of Graybug Vision and InxMed
  • Board member of Hugel Inc (kosdaq: 145020.KQ)

About
Technologies
Board of directors
Management team
Intellectual property
Research Coverage
Pipeline
Investors

Contact
Facebook X-twitter Linkedin Instagram

About
Technologies
Board of directors
Management team
Intellectual property
Research Coverage
Pipeline
Investors

Contact
Facebook X-twitter Linkedin Instagram

About
Technologies
Board of directors
Management team
Intellectual property
Pipeline
Investors

Contact
Facebook X-twitter Linkedin Instagram